All questions are shown as received by the Trust.
Q1. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib + Trametinib
d. Dacarbazine
e. Denosumab
f. Encorafenib + Binimetinib
g. Ipilimumab monotherapy
h. Ipilimumab + Nivolumab
i. Nivolumab monotherapy
j. Nivolumab + Relatlimab
k. Pembrolizumab
l. Trametinib
m. Vemurafenib
n. Vemurafenib + Cobimetinib
o. Other active systemic anti-cancer therapy
p. Palliative care only
Q2. If possible, could you please provide the patients treated in the past 3 months with the following agents for metastatic melanoma ONLY:
a. Ipilimumab monotherapy
b. Ipilimumab + Nivolumab
c. Nivolumab monotherapy
d. Nivolumab + Relatlimab
e. Pembrolizumab
f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy
h. Palliative care only
Q3. In the last 3 months, how many patients have been initiated* on the following agents for treatment for melanoma?
a. Ipilimumab (monotherapy)
b. Nivolumab (monotherapy)
c. Nivolumab AND Ipilimumab (combination)
d. Nivolumab AND Relatlimab
e. Pembrolizumab
f. Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
g. Other active systemic anti-cancer therapy
